Clinical Trial Update: NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of NTLA-3001 for Alpha-1 Antitrypsin Deficiency–associated lung disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Alpha-1 Antitrypsin Deficiency-associated Lung Disease

Drugs mentioned

• NTLA-3001

Snippet

Sponsor: Intellia Therapeutics | Conditions: Lung Disease, Pulmonary Disease | Phase 1, Phase 2 | Status: WITHDRAWN